IMUGENE LIMITED — Capital/Financing Update 2015

Feb 17, 2015

Suite 1, 1233 High Street Armadale VIC 3142

==> picture [175 x 57] intentionally omitted <==

Imugene Limited ACN 009 179 551

18 February 2015

Imugene Receives $230K Research and Development Tax Refund

Imugene Limited (ASX:IMU) has received a research and development tax refund of $230,690 as part of the Australian government’s R&D incentive program.

These funds complement Imugene’s $3.5 million capital raising announced in December and will contribute to the progression of the company’s main asset, HER-Vaxx, due to enter additional human Phase Ib/II gastric cancer clinical trials later this year.

“Imugene’s research capability is strengthened by this financial support. This clinical research on HER-Vaxx is attempting to develop much better treatments for HER2-positive gastric, breast and other cancers and is striving to help sufferers and benefit healthcare,” said Mr Charles Walker, Managing Director of Imugene.

“Our endeavour is to achieve one or more breakthroughs in these areas with superior commercial products. This non-dilutive funding helps us move down this path. I expect Imugene to continue to benefit from this innovative R&D refund scheme in future years.”

Charles Walker Managing Director Paul Hopper Tel: +61 (0) 4 5044 6990 Executive Chairman Cwalker[at]imugene.com Tel: +1 858 334 5820 (US) www.imugene.com Tel: +61 406 671 515 (Australia) receptogen[at]earthlink.net

Media contact: Rudi Michelson Monsoon Communications +61 3 9620 3333 rudim[at]monsoon.com.au

About Imugene: Imugene (ASX; IMU) is an immuno-oncology biopharmaceutical company developing HER2 positive gastric and breast cancer immunotherapies. The Company’s lead product is HER-Vaxx, a proprietary HER2 positive cancer immunotherapy that stimulates a polyclonal antibody response to HER2/neu. HER-2/neu is a known and validated receptor over-expressed on various tumours including gastric, breast, ovarian, lung and pancreatic cancers. HER-Vaxx has successfully completed a Phase I study in patients with breast cancer and the next stage of development will be a Phase Ib/II study in patients with gastric cancer. Imugene’s corporate headquarters are located in Melbourne, Australia with the scientific team in Vienna, Austria.

IMUGENE LIMITED Telephone +61 3 9824 5254 Fax +61 3 9822 7735 Website www.imugene.com